NASDAQ:TCRR - Tcr2 Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Tcr2 Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $16.01 +1.44 (+9.88 %) (As of 01/24/2020 04:00 PM ET) Add Compare Today's Range$14.77Now: $16.01▼$16.2150-Day Range$12.95MA: $15.56▼$17.8852-Week Range$10.04Now: $16.01▼$25.47Volume107,743 shsAverage Volume86,790 shsMarket Capitalization$384.72 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TCRR Previous Symbol CUSIPN/A CIKN/A Webhttp://www.tcr2.com/ Phone617-949-5200Debt Debt-to-Equity RatioN/A Current Ratio21.14 Quick Ratio21.14Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($98.53) Net Income$-24,250,000.00 Net MarginsN/A Return on Equity-40.15% Return on Assets-26.51%Miscellaneous Employees47 Outstanding Shares24,030,000Market Cap$384.72 million Next Earnings Date4/6/2020 (Estimated) OptionableNot Optionable Receive TCRR News and Ratings via Email Sign-up to receive the latest news and ratings for TCRR and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:TCRR Rates by TradingView Tcr2 Therapeutics (NASDAQ:TCRR) Frequently Asked Questions What is Tcr2 Therapeutics' stock symbol? Tcr2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR." How were Tcr2 Therapeutics' earnings last quarter? Tcr2 Therapeutics Inc (NASDAQ:TCRR) issued its earnings results on Tuesday, November, 12th. The company reported ($0.58) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by $0.03. View Tcr2 Therapeutics' Earnings History. When is Tcr2 Therapeutics' next earnings date? Tcr2 Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Tcr2 Therapeutics. What price target have analysts set for TCRR? 7 analysts have issued 12-month price targets for Tcr2 Therapeutics' stock. Their forecasts range from $16.00 to $37.00. On average, they anticipate Tcr2 Therapeutics' share price to reach $26.33 in the next twelve months. This suggests a possible upside of 64.5% from the stock's current price. View Analyst Price Targets for Tcr2 Therapeutics. What is the consensus analysts' recommendation for Tcr2 Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tcr2 Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tcr2 Therapeutics. Has Tcr2 Therapeutics been receiving favorable news coverage? News headlines about TCRR stock have been trending extremely negative on Saturday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Tcr2 Therapeutics earned a daily sentiment score of -5.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Tcr2 Therapeutics. Who are some of Tcr2 Therapeutics' key competitors? Some companies that are related to Tcr2 Therapeutics include Coherus Biosciences (CHRS), Orchard Therapeutics (ORTX), DBV TECHNOLOGIE/S (DBVT), NanoString Technologies (NSTG), Mesoblast (MESO), Aerie Pharmaceuticals (AERI), Krystal Biotech (KRYS), BAVARIAN NORDIC/S (BVNRY), Sangamo Therapeutics (SGMO), AVITA MED LTD/S (RCEL), Atara Biotherapeutics (ATRA), Adverum Biotechnologies (ADVM), Oyster Point Pharma (OYST), Vericel (VCEL) and Proteon Therapeutics (PRTO). What other stocks do shareholders of Tcr2 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tcr2 Therapeutics investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Exxon Mobil (XOM), Novavax (NVAX), Kaleido Biosciences (KLDO), LogicBio Therapeutics (LOGC), Arista Networks (ANET) and Cloudera (CLDR). Who are Tcr2 Therapeutics' key executives? Tcr2 Therapeutics' management team includes the folowing people: Dr. Garry E. Menzel, Pres, CEO & Director (Age 55)Mr. Robert Hofmeister, Chief Scientific Officer (Age 52)Dr. Alfonso Quintas Cardama M.D., Chief Medical Officer (Age 48)Mr. Mayur Amrat Somaiya, Chief Financial Officer (Age 46) When did Tcr2 Therapeutics IPO? (TCRR) raised $76 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at a price of $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers. How do I buy shares of Tcr2 Therapeutics? Shares of TCRR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Tcr2 Therapeutics' stock price today? One share of TCRR stock can currently be purchased for approximately $16.01. How big of a company is Tcr2 Therapeutics? Tcr2 Therapeutics has a market capitalization of $384.72 million. The company earns $-24,250,000.00 in net income (profit) each year or ($98.53) on an earnings per share basis. Tcr2 Therapeutics employs 47 workers across the globe.View Additional Information About Tcr2 Therapeutics. What is Tcr2 Therapeutics' official website? The official website for Tcr2 Therapeutics is http://www.tcr2.com/. How can I contact Tcr2 Therapeutics? Tcr2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-949-5200 or via email at [email protected] MarketBeat Community Rating for Tcr2 Therapeutics (NASDAQ TCRR)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 64 (Vote Outperform)Underperform Votes: 68 (Vote Underperform)Total Votes: 132MarketBeat's community ratings are surveys of what our community members think about Tcr2 Therapeutics and other stocks. Vote "Outperform" if you believe TCRR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TCRR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/25/2020 by MarketBeat.com StaffFeatured Article: What Are Cryptocurrencies?
